Why VANI lags the market
Down 16% in a year while the S&P 500 rose 7%.
- Its $14.6M in cash covers about 2 quarters at the past year's pace,
- Arithmetic on filed figures,
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 16% in a year while the S&P 500 rose 7%.
| Holding it back | 50.9% more shares than a year ago |
| Latest filing | 8-K, Nov 16 |
After its last 4 reports it closed -2.6% on average, higher 2 of 4 times.
Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
VANI is #66 of 86 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 66 |
Expected to report Thu Mar 25, after the close (in 124 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase of $0.5 million, or 11%, was primarily attributable to an increase in the clinical trial related expense from our Biopharm Division.”
VANI's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase of $0.3 million, or 14%, was primarily attributable to an increase in personnel and related expenses from our Neurostimulation Division and our Biopharm Division.”
From its results filing (SEC filing · Nov 12)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | -0.9% | -13.0% | -7.1% |
| Aug 13, 2026 | 0.0% | +4.5% | +5.2% |
| May 13, 2026 | -3.5% | +3.5% | +2.6% |
Sales grew in one of the last four years, to $0 in 2025. It lost money in each of the six years.
RSI 54.2, MACD above signal, below both averages. Not scored.
2 insiders bought $229K across 7 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: VANI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
VANI scores 0 today, which Breakaway calls Below Average. It is #66 of 86 in Medical Devices by Quality Score, with 4 of 14 chart checks firing. Down 16% in a year while the S&P 500 rose 7%. Shares: 37.2% more than a year ago (to Dec 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
VANI scores 0 today, which Breakaway calls Below Average (0 to 5). That is #66 of 86 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VANI's 0.
2 insiders bought $229K across 7 filings in the last 6 months. No open-market sales on record. The newest is Gregg Williams, 10% owner, who bought $93K on Nov 19. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.